The combination of immunotherapy, targeted therapy, and chemotherapy could be the new standard first-line treatment of patients with high-grade, advanced...
As reported in The Lancet Oncology by Egbert F. Smit, MD, and colleagues, primary analysis in the HER2-overexpressing unresectable or metastatic non–small cell cancer...
Glucagon-like peptide (GLP)-1 receptor agonists may not be associated with an increased risk of thyroid cancer, according to a recent study...
In a single-center phase II trial reported in The Lancet Oncology, Campbell et al found that cabozantinib monotherapy showed activity in adult patients...
In a systematic review and meta-analysis reported in JAMA Oncology, Sorin et al found that neoadjuvant chemoimmunotherapy was associated with better...
In a retrospective cohort study reported in the Journal of Clinical Oncology, Tilki et al found that adjuvant radiotherapy was associated with reduced risk for all-cause mortality vs early salvage radiotherapy among men at high risk for disease recurrence following radical prostatectomy. As stated ...
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
In a real-world retrospective propensity-matched cohort study reported in JAMA Network Open, Chakiryan et al found that both first-line immunotherapy and combined treatment with targeted therapy plus immunotherapy were associated with improved overall survival vs targeted therapy alone in patients...
The first results from the phase III CheckMate 648 study represent significant progress in the treatment of patients with advanced esophageal squamous cell carcinoma. The trial evaluated first-line treatment with nivolumab plus chemotherapy or nivolumab plus ipilimumab in patients with advanced...
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
In the treatment of relapsed/refractory follicular lymphoma, a comparison of data from the ZUMA-5 trial with those of the external control cohort of the SCHOLAR-5 trial showed substantial improvement in all clinical endpoints with axicabtagene ciloleucel. John G. Gribben, DSc, FRCP, FRCPath,...
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...